RetinalGenix Technologies Inc. reported its financial results for the second quarter and first half of 2026, revealing a continued lack of revenue generation alongside significant operational changes. For the three months ending June 30, 2026, the company recorded a net loss of $307,397, a 53% improvement from the $649,418 loss reported in the same period of 2025. Over the first half of 2026, the net loss was $897,886, down 27% from $1,236,677 in the prior year. The company has not generated any revenue since its inception, maintaining an accumulated deficit of approximately $18.8 million as of June 30, 2026.
Operating expenses for the second quarter decreased by 53% to $303,442, compared to $648,348 in the same quarter of 2025. This reduction was primarily driven by a significant decrease in general and administrative expenses, which fell by 45% to $212,254, and a 90% drop in stock-based compensation expenses to $24,782. Research and development expenses, however, increased dramatically by 360% to $66,406, reflecting the company's investment in the development of its RetinalCam™ device, a portable ophthalmic screening tool.
In terms of strategic developments, RetinalGenix has engaged with Pearl IRB to conduct a study aimed at personalizing medical evaluations for patients receiving intraocular injections for wet macular degeneration. The company anticipates expanding this study to multiple states by early 2027. Additionally, RetinalGenix is progressing with its plans to conduct pharmaceutical clinical studies for two products targeting dry age-related macular degeneration and Alzheimer’s syndrome dementia.
The company’s cash position remains precarious, with only $27,232 on hand as of June 30, 2026, and liabilities totaling approximately $2.7 million. RetinalGenix has indicated that it will require an additional $7 million to fund ongoing operations and product development. The company is actively seeking additional financing through equity sales and strategic partnerships, although it acknowledges the uncertainty surrounding its ability to secure such funding. The management has expressed substantial doubt about the company's ability to continue as a going concern without raising additional capital.
Looking ahead, RetinalGenix plans to launch its RetinalCam™ device in the second half of 2026, although it does not expect to generate revenue from this product until after its development is completed and regulatory approvals are obtained. The company remains focused on its mission to prevent vision loss and blindness through innovative ophthalmic technologies, while navigating the challenges of funding and operational sustainability.
About RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc. develops ophthalmic devices and genetic testing solutions to enable early detection, monitoring, and treatment of eye and systemic diseases such as macular degeneration, diabetic retinopathy, and Alzheimer's. Its core products include retinal imaging systems and pharmacogenetic mapping platforms, serving healthcare providers, clinics, and patients. The company focuses on innovative, non-invasive diagnostics and therapeutics to improve disease management and prevent vision loss.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov